Latanoprost/Timolol Olikla (Timolol Maleate, Latanoprost)

The drug combines two mechanisms: latanoprost, a prostaglandin analog, increases fluid outflow through the uveoscleral pathway, while timolol, a non‑selective beta‑blocker, reduces aqueous humor production. Together they provide a greater pressure‑lowering effect than either agent alone.

The dosing regimen for Latanoprost/Timolol Olikla is determined by the prescribing ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily, but the exact dose and frequency should follow the individual prescriber's instructions.

Safety data for use during pregnancy or lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the fixed‑dose combination offers superior intra‑ocular pressure reduction and simplifies dosing. It may be preferred over separate agents when patients need both increased outflow and decreased production, reducing the number of daily eye‑drops and improving adherence.

Latanoprost/Timolol Olikla should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not use if the solution appears discolored or contains particles.

The medication is applied as an ocular solution. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and instill one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe allergic reactions (e.g., angioedema), significant increase in intra‑ocular pressure, corneal ulceration, vision loss, and systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm, especially in patients with underlying cardiac or respiratory conditions.

Patients with known hypersensitivity to timolol, latanoprost, or any component of the formulation should avoid use. Those with severe asthma, chronic obstructive pulmonary disease, bradycardia, heart block, or uncontrolled heart failure should not use this product without medical supervision.